Recombinant Cynomolgus c-Met Protein (aa 1-932) [Fc] (VAng-Cr4010)
Recombinant Cynomolgus c-Met Protein (Met1-Thr932) fused with a Fc tag at C-terminus was expressed in HEK293 Cells, with a molecular weight of 128.3 kDa. (Accession ID: NP_001162100.1)
Formulation
Lyophilized from sterile PBS, pH 7.4.
Purity
> 95% pure by SDS-PAGE.
Storage
Store at -20°C to -80°C.
Introduction
c-Met is a single pass tyrosine kinase receptor essential for embryonic development, organogenesis and wound healing. Hepatocyte growth factor/Scatter Factor (HGF/SF) and its splicing isoform (NK1, NK2) are the only known ligands of the MET receptor. MET is normally expressed by cells of epithelial origin, while expression of HGF/SF is restricted to cells of mesenchymal origin. Abnormal MET activation in cancer correlates with poor prognosis, where aberrantly active MET triggers tumor growth, formation of new blood vessels (angiogenesis) that supply the tumor with nutrients, and cancer spread to other organs (metastasis). MET is deregulated in many types of human malignancies, including cancers of kidney, liver, stomach, breast, and brain. Normally, only stem cells and progenitor cells express MET, which allows these cells to grow invasively in order to generate new tissues in an embryo or regenerate damaged tissues in an adult.
Alternative Names
MET; MET proto-oncogene; receptor tyrosine kinase; AUTS9; HGFR; RCCP2
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.